NICE have recommended Enhertu for the treatment of HER2-positive breast cancer within a managed acce...
Read moreWe summarise four handpicked articles from pharmaceutical, pricing and market access that are worth ...
Read moreOur experts reflect on the trends that shaped the European pricing and market access landscape in 20...
Read moreOur Market Access Analysts discuss the proposed changes to CAR-T reimbursement in the US and conside...
Read moreThe report looks at how differences in cancer survival rates between the UK and other countries have...
Read moreAccording to the Department of Health and Social Care (DHSC), the commitments will enable patients t...
Read moreCell and gene therapies - life saving opportunity for many patients
Read moreThe development of gene therapies represents a new frontier of science, with the potential to help p...
Read more